Brandon D. Minde Certified By the Supreme Court of New Jersey as a Criminal Trial Attorney

Dughi, Hewit & Domalewski, P.C., is pleased to announce that Brandon D. Minde has been certified  by the Supreme Court of New Jersey as a Criminal Trial Attorney.

Brandon is a partner with the firm and leads the firm’s criminal defense practice.

Attorneys may be designated by the Supreme Court of New Jersey as “certified attorneys” if they: are able to demonstrate sufficient levels of experience, education, knowledge and skill in a specific area of law or practice; have passed a rigorous examination; and have been recognized by their peers as having sufficient skills and reputation in the designated specialty.

The firm congratulates Brandon on this achievement.

FIVE DUGHI, HEWIT & DOMALEWSKI ATTORNEYS HONORED AS SUPER LAWYERS AND RISING STARS FOR 2019

Dughi, Hewit & Domalewski is proud to announce that partners of the firm – Louis John Dughi, Jr. and Craig A. Domalewski – have been named by New Jersey Super Lawyers magazine as among the top attorneys in New Jersey for 2019.  Each year, no more than five percent of the lawyers in the state are selected by Super Lawyers to receive this honor.

In addition, the firm is also proud to announce that Cyndee L. Allert, Brandon D. Minde and Jennifer L. Young were named to the 2019 New Jersey Rising Stars list. Each year, this designation is given to less than 2.5 percent of New Jersey attorneys recognized as the top up-and-coming attorneys who are 40 years old or younger, or who have been practicing for 10 years or less.

Super Lawyers, a Thomson Reuters business, is a rating service of outstanding lawyers from more than 70 practice areas who have attained a high degree of peer recognition and professional achievement. The annual selections are made using a patented multiphase process that includes a statewide survey of lawyers, an independent research evaluation of candidates and peer reviews by practice area. For more information about Super Lawyers, visit SuperLawyers.com.

DHD Litigators to Present: The ABC’s of Civil and Criminal Trial Preparation in New Jersey

Dughi, Hewit & Domalewski, P.C. is proud to announce that Louis John Dughi, Jr.Craig A. DomalewskiMary Elizabeth Gazi, and Brandon D. Minde will be presenting an online seminar on New Jersey trial preparation on Tuesday, February 26, 2019 at 12:00pm EST (estimated duration: 75 minutes).

A trial is the culmination of the preparation of the case – preparation that has been designed from the start of discovery to develop the facts and evidence to win at trial. The trial attorney must start at the end (what needs to be proven at trial) to identify the elements of each claim and defense and then design a Blueprint of how he or she will develop and establish the facts and evidence to support the claims and defenses of the case. Like any building process, there are multiple stages to design, assess and redesign the Blueprint and strategies. The final Blueprint is a trial notebook that defines trial themes and organizes the presentation of the facts and evidence by witness to prove the facts needed to win. An effective trial book keeps the trial attorney focused and instills confidence that he or she is prepared and ready.

In this program, partners at Dughi, Hewit & Domalewski, P.C., a premier New Jersey boutique law firm with extensive litigation and trial experience, will help the practitioner learn to develop a Blueprint as it pertains to written discovery, fact deposition and expert discovery, dispositive and pre-trial motions, rules of evidence, trial issues and more when litigating New Jersey cases and getting those cases ready for trial.

Learning Objectives:

  • Outline the Blueprint of the case, which becomes the blueprint for the trial
  • Determine the theme for the trial
  • Prepare the witness examinations and exhibits required to explain and prove the case
  • Create a Trial Book to organize witness examinations, documents and exhibits
  • Present and repeat the trial themes from opening statement to closing argument

This webcast will stream live on Tuesday, February 26, 2019 at 12:00pm EST (estimated duration: 75 minutes) and will be taught by Louis John Dughi, Jr.Craig A. DomalewskiMary Elizabeth Gazi, and Brandon D. Minde.  To register for the webcast, click on the link listed below.

Accreditation:

  • NJ – 1.5 New Jersey Civil or Criminal Trial Preparation
  • NY – 1.5 Professional Practice

To register: 

CMS Drug Price Proposal Would Harm Patients, Providers

On October 25th, the Centers for Medicare and Medicaid Services released a proposal to implement an international drug Pricing Index Model that would slash Medicare Part B reimbursement to physicians and hospital outpatient departments and interpose a new middleman into the drug supply chain.  In an article published by Law 360 on November 1st, Justin Linder describes how the proposal is likely to harm patients and providers while doing very little to move the needle on drug prices.

Read the full article: CMS Drug Price Proposal Would Harm Patients, Providers

Craig A. Domalewski selected for inclusion in the 2019 edition of Best Lawyers®

Dughi, Hewit & Domalewski, P.C. is proud to announce that Craig A. Domalewski has been selected for inclusion in the 2019 edition of Best Lawyers®, the oldest and most respected peer-review publication in the legal profession.

About Best Lawyers®

Best Lawyers is the oldest and most respected peer-review publication in the legal profession. A listing in Best Lawyers is widely regarded by both clients and legal professionals as a significant honor, conferred on a lawyer by his or her peers. For more than three decades, Best Lawyers lists have earned the respect of the profession, the media, and the public, as the most reliable, unbiased source of legal referrals anywhere.

Justin C. Linder to Present on 340B Drug Discount Program Changes and Status at 2018 American Health Lawyers Association Fraud & Compliance Forum in Baltimore on September 27th

Justin C. Linder to Present on 340B Drug Discount Program Changes and Status at 2018 American Health Lawyers Association Fraud & Compliance Forum in Baltimore on September 27th

2018 has ushered in significant changes to the 340B drug discount program, with a nearly 30% reduction in Medicare reimbursement for most 340B hospitals accompanied by the proliferation of compliance audits by the Health Resources and Services Administration and its contractors.  Additionally, the program has become the subject of sustained scrutiny from Congress and the Government Accountability Office, among others, as industry stakeholders and politicians contend that the program is overbroad and insufficiently regulated.

To provide valuable perspective on these ongoing developments, Justin Linder, head of Dughi, Hewit & Domalewski’s Healthcare and Life Sciences practice, will be moderating a panel at the upcoming American Health Lawyers Association Fraud & Compliance Forum in Baltimore, MD on September 27, from 3:15-4:15 pm, with Cindy Bartlett and Moira Gibbons, respectively, the CCOs for Bon Secours Health System and St. Joseph’s Health in Paterson, New Jersey.

We invite you to attend what promises to be an informative session, and hope to see you in Baltimore!  For your reference, a brief description of the program is provided below.

2018 Fraud & Compliance Forum, Renaissance Harborplace Hotel, Baltimore, MD (Sept. 26-28)

340B’s Tumultuous Year: Program Status and Trends in Auditing, Compliance and Reimbursement

Scheduled: Thursday, September 27 from 3:15-4:15 pm

The 340B program has drawn recent attention from CMS, on Capitol Hill and in the courts. In the wake of a Medicare reimbursement reduction for certain 340B entities, an uptick in HRSA audits, the introduction of new coding modifiers and calls for far-ranging program revisions by some in Congress and the pharmaceutical industry, the panel will reflect on the status of the program, the impact of reimbursement changes, and trends in compliance and auditing. The session will focus on the following topics, among others:

  • Changes to CMS reimbursement for 340B discounted drugs imposed under the 2018 Outpatient Prospective Payment System Final Rule (OPPS Final Rule), including Medicare reimbursement reductions to certain 340B covered entities and the implementation of a new modifier system on all 340B entities.
  • Strategies to promote compliance with 340B drug diversion, duplicate discount and GPO prohibitions.
  • The HRSA audit process and practical advice from the perspective of 340B covered entity compliance officers.
  • The status of the American Hospital Association’s lawsuit seeking to enjoin the 340B payment reduction and legislative efforts to transform the program.
  • Further modifications to 340B reimbursement advanced in the 2019 OPPS Proposed Rule.

United Healthcare’s OptumRx Accused of Defrauding Benefit Plan

Pharmacy Benefit Managers are being subjected to increasing scrutiny as purported drivers of pharmaceutical costs.  Justin Linder discusses the various fronts in the rhetorical and legal battle against PBMs and how restrictions imposed on PBMs have the potential to impact the pharmaceutical supply chain in an August 28, 2018 Bloomberg Law article.

Read the full article: United Healthcare’s OptumRx Accused of Defrauding Benefit Plan

Hospitals Lose Challenge to Rate Cuts for Safety-Net Drugs

In a July 17th Order, the U.S. Court of Appeals for the District of Columbia dealt the latest blow to hospital groups’ challenge to the January 1, 2018 Medicare reimbursement reduction for drugs purchased under the 340B discount drug program, affirming the district court’s dismissal of the case on presentment grounds.  Justin Linder discussed the implications of this development in a July 17th article published by Bloomberg Law.

Read the full article: Hospitals Lose Challenge to Rate Cuts for Safety-Net Drugs

Are Private Equity Firms the New Health-Care Fraud Target?

Private equity firms were placed on notice recently they may fall into an expanding False Claims Act liability net after the DOJ revealed it will proceed against one such firm for alleged fraud by a compounding pharmacy in which it held a majority stake.  Justin C. Linder discussed the implications of the DOJ’s decision to intervene in U.S. ex rel. Medrano v. Diabetic Care Rx, LLC in the June 1 issue of Bloomberg Law News.

Read the complete article: Are Private Equity Firms the New Health-Care Fraud Target?